Tissue factor pathway inhibitor (TFPI) antigen plasma level in patients with interstitial lung disease before and after heparin administration

Seminars in Thrombosis and Hemostasis

Volumn 23, Issue 1, 1997, Pages 45-49

  Cella, Giuseppe ^a   Cipriani, Angiolo ^b   Tommasini, Andrea ^b   Rampin, Ernesto ^a   Sbarai, Alessandra ^a   Rocconi, Roberta ^a   Mazzaro, Gabriella ^a   Luzzatto, Guido ^a  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

factor VIIa tissue factor; heparin; idiopathic pulmonary fibrosis; sarcoidosis; Tissue factor pathway inhibitor (TFPI)

Indexed keywords

BLOOD CLOTTING FACTOR 7A; HEPARIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; BLOOD CLOTTING; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; INFLAMMATION; INTERSTITIAL LUNG DISEASE; LEUKOCYTE COUNT; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MESANGIUM CELL; MESENCHYME; PRIORITY JOURNAL; SARCOIDOSIS; THORAX RADIOGRAPHY;

EID: 0030958509     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-996069     Document Type: Article

References (23)

1. Chapman HA, CL Allen, OL Stone: Abnormalities in pathways of alveolar fibrin turnover among patients with interstitial lung disease. Am Rev Respir Dis 133:437-443, 1986.
2. Robinson BWS: Production of plasminogen activator by alveolar macrophages in normal subjects and patients with interstitial lung disease. Thorax 43:508-515, 1988.
3. Idell S, KK James, EG Levin, BS Schwartz, N Manchanda, RJ Maunder, TR Martin, J McLarty, DS Fair: Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome. J Clin Invest 84:695-705, 1989.
4. Nakstad B, T Lyberg, OH Skjonsberg, NP Boye: Local activation of the coagulation and fibrinolysis system in lung disease. Thromb Res 57:827-838, 1990.
5. Chapman HA, DS Fair, CL Allen, OL Stone: Human macrophages synthesize factor VII. Possible role in interstitial lung disease. J Clin Invest 75:2030-2037, 1985.
6. Østerud B, MS Bajaj, SP Bajaj: Sites of tissue factor pathway inhibitor (TFPI) and tissue factor expression under physiologic and pathologic conditions. Thromb Haemostas 73:873-875, 1995.
7. Werling RW, LR Zacharski, W Kisiel, SP Bajaj, VA Memoli, SM Rousseau: Distribution of tissue factor pathway inhibitor in normal and malignant human tissues. Thromb Haemostas 69:366-369, 1993.
8. Novotny WF: Tissue factor pathway inhibitor. Semin Thromb Hemostas 20:101-108, 1994.
9. Sanset PM, U Abildgaard, ML Larsen: Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 50:803-813, 1988.
10. Cella G, U Vertolli, A Naso, A Vianello, E Rampin, A Sbarai, G Boeri, EW Strauss: Tissue factor pathway inhibitor (TFPI) activity in uremic patients during hemodialysis. Thromb Res 81: 671-677, 1996.
11. Harenberg J, R Malsch, M Angelescu, C Lange, H-C Michaelis, H Wolf, DL Heene: Anticoagulant effect and tissue factor pathway inhibitor after intrapulmonary low-molecular-weight heparin. Blood Coag Fibrinolysis 7:477-483, 1996.
12. De Moerloose P, E De Benedetti, L Nicod, C Vifian, G Reber: Procoagulant activity in bronchoalveolar fluids: No relationship with tissue factor pathway inhibitor activity. Thromb Res 65: 507-518, 1992.
13. Sabharwal AK, SP Bajaj, A Ameri, SM Tricomi, TM Hyers, TE Dahms. FB Taylor, MS Bajaj: Tissue factor pathway inhibitor and von Willebrand factor antigen levels in adult respiratory distress syndrome and in a primate model of sepsis. Am J Respir Crit Care Med 151:758-767, 1995.
14. Semenzato G, M Chilosi, E Ossi, L Trentin, G Pizzolo, A Cipriani, C Agostini, R Zambello, G Marcer, G Gasparotto: Bronchoalveolar lavage and lung histology. Comparative analysis of inflammatory immunocompentent cells in patients with sarcoidosis and hypersensitivity pneumonitis. Am Rev Respir Dis 132:400-404, 1985.
15. Agostini C, S Garbisa, L Trentin, R Zambello, G Fastelli, M Onisto, A Cipriani, G Festi, D Casara, G Semenzato: Pulmonary alveolar macrophages from patients with active sarcoidosis express type IV collagenolytic proteinase. An enzymatic mechanism for influx of mononuclear phagocytes at sites of disease activity. J Clin Invest 84:605-612, 1989.
16. Bognacki J, J Hammelburger: Functional and immunologic methods for the measurement of human tissue factor pathway inhibitor. Blood Coag Fibrinolysis 6:S65-S72, 1995.
17. Jeske W, D Hoppensteadt, J Fareed, E Bermes: Measurement of functional and immunological levels of tissue factor pathway inhibitor. Some methodologic considerations. Blood Coag Fibrinolysis 6:S73-S80, 1995.
18. Kokawa T, K-I Enjyoji, K Kumeda, Y-I Kamikubo, M Harada-Shiba, H Koh, M Tsushima, A Yamamoto, H Kato: Measurement of the free form of TFPI antigen in hyperlipidemia. Relationship between free and endothelial cell-associated forms of TFPI. Arteriosclerosis Thromb Vasc Biol 16:802-808, 1996.
19. Yamabe H, H Osawa, H Inuma, M Kaizuka, N Tamura, S Tsunoda, Y Fujita, K Shirato, K Onodera: Tissue factor pathway inhibitor production by human mesangial cells in culture. Thromb Haemostas 76:215-219, 1996.
20. Ameri A, MN Kuppuswamy, S Basu, SF Bajaj: Expression of tissue factor pathway inhibitor by cultured endothelial cells in response to inflammatory mediators. Blood 79:2319-2326, 1992.
21. Raghu G: Idiopathic pulmonary fibrosis. A rational clinical approach. Chest 92:148-154, 1987.
22. Sandset PM, H Lund, J Norseth, U Abildgaard, L Ose: Treatment with hydroxyethylglutaryl-coenzyme A reductase inhibitors in hypercholesterolemia induces changes in the components of the extrinsic coagulation system. Arterioclerosis Thromb Vasc Biol 11:138-145, 1991.
23. Hansen J-B, KR Huseby, N-E Huseby, PM Sandset, T-A Hanssen, A Nordoy: Effect of cholesterol lowering on intravascular pools of TFPI and its anticoagulant potential in type II hyperlipoproteinemia. Arterioclerosis Thromb Vasc Biol 15:879-885, 1995.